ALKLH.PA KLEA HOLDING
- Market cap
- EUR 48.2M
- P/E
- -
- P/B
- 1.73x
- ROE
- 8.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ALKLH.PA undervalued?
Graham numberThe Graham number of KLEA HOLDING cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KLEA HOLDING fundamental analysis
No fundamental analysis for KLEA HOLDING yet.
KLEA HOLDING stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KLEA HOLDING
Klea Holding SA, together with its subsidiaries, develops health technologies and services in France, the United Arab Emirates, and Saudi Arabia. It operates digitalized medical centers that provide administrative screenings for residency and work visas, preventive health check-ups, and medical fitness tests under the Smart Salem brand. In addition, the company engages in the production of pharmaceuticals. The company was formerly known as Visiomed Group SA and changed its n…
Full company profileKLEA HOLDING financial statements
KLEA HOLDING annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 9.49M | 10.5M | 8.74M | 10.2M | 19.0M | 7.17M | 14.4M | 13.7M | 17.3M | 22.2M |
| Gross Profit | -6.80M | -5.77M | -7.46M | -7.90M | -3.76M | -715K | 3.20M | 6.30M | 8.25M | 9.79M |
| Operating Income | -13.6M | -9.15M | -18.4M | -21.9M | -6.58M | -3.68M | -4.37M | 787K | 1.67M | 3.68M |
| EBITDA | -12.7M | -12.8M | -19.2M | -20.3M | -4.53M | -3.24M | -2.21M | 5.85M | 2.66M | 5.20M |
| Net Income | -13.4M | -13.2M | -19.8M | -24.1M | -5.15M | -4.46M | -5.28M | 902K | 1.41M | 2.28M |
| EPS | -27 | -11 | -11 | -1.68 | -0.20 | -0.03 | -0.02 | 0.00 | 0.00 | 0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 19.4M | 20.1M | 18.5M | 14.7M | 5.91M | 44.1M | 36.1M | 36.6M | 37.8M | 37.3M |
| Total Liabilities | 11.3M | 7.47M | 18.2M | 19.8M | 10.3M | 30.0M | 11.8M | 11.8M | 10.0M | 9.68M |
| Shareholders' Equity | 8.15M | 12.7M | 361K | -5.11M | -4.41M | 14.1M | 24.3M | 24.1M | 28.0M | 27.6M |
| Cash & Short-term Investments | 6.51M | 3.46M | 630K | 6.89M | 810K | 6.57M | 2.36M | 2.97M | 3.31M | 5.25M |
| Total Debt | 3.48M | 62.2K | 2.77M | 3.03M | 15.0K | 4.95M | 5.62M | 7.93M | 5.88M | 5.37M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -11.8M | -16.4M | -12.3M | -22.7M | -10.9M | -6.50M | -1.74M | 1.11M | 932K | 4.93M |
| Capital Expenditure | 941K | 672K | 774K | 56.0K | 245K | 196K | 5.52M | 2.61M | 766K | 1.03M |
| Free Cash Flow | -12.7M | -17.1M | -13.0M | -22.8M | -11.1M | -6.70M | -7.26M | -1.50M | 166K | 3.90M |
| Ratios | ||||||||||
| ROE | -164.6% | -103.9% | -5,481.2% | - | - | -31.7% | -21.7% | 3.7% | 5.0% | 8.3% |
| ROA | -69.1% | -65.3% | -106.8% | -163.3% | -87.2% | -10.1% | -14.6% | 2.5% | 3.7% | 6.1% |
| Net Profit Margin | -141.3% | -125.8% | -226.4% | -235.0% | -27.1% | -62.1% | -36.5% | 6.6% | 8.1% | 10.3% |
| Debt to Equity | 0.43x | 0.00x | 7.67x | - | - | 0.35x | 0.23x | 0.33x | 0.21x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
KLEA HOLDING dividends
KLEA HOLDING has not paid dividends in the last 10 fiscal years.
Last stock split: 1:40 on Mar 19, 2020.
Who owns KLEA HOLDING
- Insiders 0.00%
- Institutions 0.97%
- Public & others 99.03%
- Shares outstanding 306M
- Free float 187M
KLEA HOLDING company profile
- Company name
- KLEA HOLDING
- Ticker
- ALKLH.PA
- ISIN
- FR0013481835
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 112
- Fiscal year end
- December
- Address
- 34 Rue Laffitte, Paris, France, 75009
- Phone
- 33 1 80 27 29 90
- Website
- kleaholding.com
About KLEA HOLDING
Klea Holding SA, together with its subsidiaries, develops health technologies and services in France, the United Arab Emirates, and Saudi Arabia. It operates digitalized medical centers that provide administrative screenings for residency and work visas, preventive health check-ups, and medical fitness tests under the Smart Salem brand. In addition, the company engages in the production of pharmaceuticals. The company was formerly known as Visiomed Group SA and changed its name to Klea Holding SA in June 2024. Klea Holding SA was founded in 2007 and is headquartered in Paris, France.
KLEA HOLDING management
1- Mr. Raphael SmilaCEO & Director